result shock rp japan earn power keep us bullish name
morn report fiscal result guidanc line
pre-announce see detail highlight call view shock
util believ surgeon-l call action posit contribut
factor written second rp account sale
last quarter show rp site site
util exist site acceler third encourag well
ahead schedul japan open project site despit method launch
lastli earn power best class expect continu cost control given higher
op margin provid today vs previous bottom line continu
encourag investor purchas share even current level
report fiscal revenu growth beat
estim growth despit face tough comp us impella sale
strong growth street estim
gross margin last year bp higher
estim result record product partial off-set consol placement
new manufactur line headcount add oper margin came solid
higher model bottom line ep includ
million p/ due primarili recent enact tax reform act
excess tax benefit stock-bas comp taken togeth abmd adjust ep
beat
thought guidanc line pre-announce op margin rais
manag rais full fiscal year guidanc rang growth
repres increas midpoint prior rang
came ahead street model growth face
difficult comp year believ manag bake conservat
gener take rout came ahead street guid
impli deceler despit strong momentum compani key growth
area lastli earn power stori among best med tech
manag vs previous
point call post anoth impress quarter
three key point want address first highlight quarter view
emerg util come impress vs last quarter
physician-l call action perhap contributor acceler
written anticip util impella cardiogen shock
patient rise come quarter continu follow page
develop manufactur circulatori support devic
sale
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
second compani comment rp account sale repres
acceler sequenti view strong posit impella rp
place site quarter total util exist site
acceler well continu anticip right side product facilit broader sell
impella beyond lastli though compani plan commerci slowli
japan encourag well ahead schedul key market open
project site year compani report region
stock stori continu impress remain favorit mid-
cap name encourag result stori continu move right direct
would surpris guidanc prove conserv given stellar momentum key
growth area japan rp specif plu core busi remain strong
intern acknowledg lofti valuat view one
differenti name med tech long runway growth ahead strong earn
power collect support share come quarter allow compani
grow larg cap name long-term
maintain ow-rat increas pt increas price target
base sale assum net cash share
outstand roll forward multipl
increas target multipl increas confid long term term growth driver
cardiogen shock commerci japan impella rp drive multipl higher
page
sourc compani report piper jaffray co estim
page
good gener incom expens net incom net incom analysi gross gener analysisu impella impella abiom
thousand except per share data
good sold
good sold
percent sale
good sold
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
